Feed / QDEL

QuidelOrtho Corporation

QDEL

Healthcare · 11.79 -3.1% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

QuidelOrtho Corporation's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 14 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.

Company-3.1% todayVolume comparison unavailable
Market group0 of 14 activeLogistics & Asset Management · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • QDEL's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if QDEL's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Devices

No new filing conclusion is available. 0 of 14 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • QDEL's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods6
Price observations320
Usable filing statements133
Verified relationships9
Evidence supporting the case
  • Operating margin changed +36.8 percentage points in the latest annual period.
  • Net margin changed +32.3 percentage points in the latest annual period.
  • Demand and volume has repeated favorable evidence across 4 filings.
Evidence challenging the case
  • Latest annual revenue changed -1.9% year over year.
  • Product pipeline and R&D has repeated adverse evidence across 4 filings.
  • Restructuring and cost reductions has repeated adverse evidence across 4 filings.
  • Foreign exchange has repeated adverse evidence across 3 filings.
Questions before a position
  • EV/sales is 69% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 11, 2026

11.79
6m-47.9%12m-57.9%24m—
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2022-01-02$1.7B+2.2%$16.43-1.6%
2023-01-01$3.3B+92.3%$9.56+33.8%
2023-12-31$3.0B-8.2%$-0.15+16.4%
2024-12-29$2.8B-7.2%$-30.54+0.6%
2025-12-28$2.7B-1.9%$-16.69+0.9%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesmixed · 4 filings
“Cash provided by financing activities was $17.6 million for the three months ended March 30, 2025 and was primarily related to net proceeds from the Revolving Credit Facility of $52.0 million, partially offset by payments on long-term borrowings of $36.0 mill…”
10-Q · May 6, 2026 ↗
Demand and volumemixed · 4 filings
“In addition, during the first quarter of 2026, we experienced delays in certain EMEA orders due to the ongoing conflicts in the Middle East.”
10-Q · May 6, 2026 ↗
Product pipeline and R&Dnegative · 4 filings
“24 Research and Development Expense Research and development expense for the three months ended March 29, 2026 decreased by $8.3 million, or 15.6%, to $44.9 million from $53.2 million for the same period in the prior year, primarily due to lower third-party m…”
10-Q · May 6, 2026 ↗
Restructuring and cost reductionsnegative · 4 filings
“Our cash requirements fluctuate as a result of numerous factors, including cash generated from operations, progress in R&D, capital expansion projects and acquisition, restructuring and business development activities.”
10-Q · May 6, 2026 ↗

Valuation discipline

Descriptive valuation snapshot

Price/sales 0.3× · EV/sales 1.2×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

11.79-3.1% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for QDEL. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for QDEL. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind QDEL

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

GRFSFiling-linked namepartnerFeb 19, 2026 ▾

“The Company has the Joint Business between Ortho and Grifols, under which Ortho and Grifols agreed to pursue a collaboration relating to Ortho’s Hepatitis and HIV diagnostics business.”

ABTAbbott LaboratoriescompetitorFeb 19, 2026 ▾

“Some of our principal competitors include, among others, Abbott Laboratories, bioMérieux, Bio-Rad, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters Corporation (acquired BD Diagnostics division) and We…”

Depended on by

BIOBio-Rad Laboratories, Inc.competitorFeb 13, 2026 ▾

“Major competitors for our products in the Clinical Diagnostics segment include Abbott Laboratories, Becton Dickinson, bioMérieux, Danaher, DiaSorin, Werfen, QuidelOrtho, Roche, Siemens Healthineers, Thermo Fisher Scientific and Tosoh.”

Filing peers

RVTYAAZTA

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 11 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

QDEL is currently a Follower in the organic co-movement group Logistics & Asset Management. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for QDEL; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.